1 Growth Stock With Major Catalysts on the Way to Buy and Hold
After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.However, Eli Lilly is gaining momentum, and expects significant catalysts that could send its stock price soaring in 2025. Even beyond those catalysts, Lilly remains an excellent buy-and-hold option for long-term investors.It's no secret that Eli Lilly is one of the leaders in the market for weight management drugs. The company's dual GLP-1/GIP medicine, Zepbound (tirzepatide), generated almost $5 billion in sales last year after being approved in late 2023.Continue reading
After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.
However, Eli Lilly is gaining momentum, and expects significant catalysts that could send its stock price soaring in 2025. Even beyond those catalysts, Lilly remains an excellent buy-and-hold option for long-term investors.
It's no secret that Eli Lilly is one of the leaders in the market for weight management drugs. The company's dual GLP-1/GIP medicine, Zepbound (tirzepatide), generated almost $5 billion in sales last year after being approved in late 2023.
